News archives


OCTOBER - DECEMBER 17

JULY - SEPTEMBER 17

APRIL - JUNE 17

JANUARY - MARCH 17

OCTOBER - DECEMBER 16

JULY - SEPTEMBER 16

APRIL - JUNE 16

JANUARY - MARCH 16

OCTOBER - DECEMBER 15

JULY - SEPTEMBER 15

APRIL - JUNE 15

JANUARY - MARCH 15

OCTOBER - DECEMBER 14

JULY - SEPTEMBER 14

APRIL - JUNE 14

JANUARY - MARCH 14

OCTOBER - DECEMBER 13

JULY - SEPTEMBER 13

APRIL - JUNE 13

JANUARY - MARCH 13

OCTOBER - DECEMBER 12

JULY - SEPTEMBER 12

APRIL - JUNE 12

JANUARY - MARCH 12

OCTOBER - DECEMBER 11

JULY - SEPTEMBER 11

APRIL - JUNE 11

JANUARY - MARCH 11

OCTOBER - DECEMBER 10

JULY - SEPTEMBER 10

APRIL - JUNE 10

JANUARY - MARCH 10

OCTOBER - DECEMBER 09

JULY - SEPTEMBER 09

APRIL - JUNE 09

JANUARY - MARCH 09

OCTOBER - DECEMBER 08

JULY - SEPTEMBER 08

APRIL - JUNE 08

JANUARY - MARCH 08

OCTOBER - DECEMBER 07

JULY - SEPTEMBER 07

APRIL - JUNE 07

JANUARY - MARCH 07

 
  current news   Press   selected story    
     
  17 April 2014  
  BIG3 inhibits insulin granule biogenesis and insulin secretion
 
 



Authors
Hongyu Li1,2, Shunhui Wei2, Kenneth Cheng3,4, Natalia V Gounko1,5, Russell E Ericksen2, Aimin Xu3,4,6, Wanjin Hong*,1 and Weiping Han*,2

1   Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR),      Singapore, Singapore
2   Singapore Bioimaging Consortium, Agency for Science, Technology and Research (A*STAR),      Singapore, Singapore
3    State Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, Hong Kong, China
4   Department of Medicine, University of Hong Kong, Hong Kong, China
5   Joint IMB‐IMCB Electron Microscopy Suite, Agency for Science, Technology and Research (A*STAR),      Singapore, Singapore
6   Pharmacology and Pharmacy, University of Hong Kong, Hong Kong, China

* Corresponding author

Published online in EMBO Reports on 7 April 2014.

Abstract

While molecular regulation of insulin granule exocytosis is relatively well understood, insulin granule biogenesis and maturation and its influence on glucose homeostasis are relatively unclear. Here, we identify a novel protein highly expressed in insulin‐secreting cells and name it BIG3 due to its similarity to BIG/GBF of the Arf‐GTP exchange factor (GEF) family. BIG3 is predominantly localized to insulin‐ and clathrin‐positive trans‐Golgi network (TGN) compartments. BIG3‐deficient insulin‐secreting cells display increased insulin content and granule number and elevated insulin secretion upon stimulation. Moreover, BIG3 deficiency results in faster processing of proinsulin to insulin and chromogranin A to β‐granin in β‐cells. BIG3‐knockout mice exhibit postprandial hyperinsulinemia, hyperglycemia, impaired glucose tolerance, and insulin resistance. Collectively, these results demonstrate that BIG3 negatively modulates insulin granule biogenesis and insulin secretion and participates in the regulation of systemic glucose homeostasis.



Figure

Figure legend: Synopsis

This study identifies a regulatory role for the novel protein BIG3 in systemic metabolism through its inhibitory effects on insulin granule biogenesis and insulin secretion.

· BIG3 is associated with immature insulin granules in pancreatic βcells.

· BIG3 restricts prohormone processing and insulin granule biogenesis.

· BIG3 deficiency results in elevated insulin content and insulin secretion.

· BIG3knockout mice show postprandial hyperglycemia and insulin resistance.


For more information on Weiping HAN’s laboratory, please click here.

For more information on Wanjin HONG’s laboratory, please click here.